This past summer, the FDA approved the application of Zhejiang Huahai Pharmaceutical Co. to produce a generic form of Viramune, an AIDS drug developed by Boehringer Ingelheim. Zhejiang Huahai must wait until May 2012 to being marketing the drug in the US, because Boehringer Ingelheim has patent protection for Viramune until then. The approval was the first time a China-based pharmaceutical company has received FDA approval to market finished pills in the US. More details...